Skip to main content

Experimental Haematology Laboratory (HEMEXP)

The Experimental Haematology Laboratory is dedicated to fundamental and applied research in the field of haematology and immunology. It operates in symbiosis with the Institut Bordet Haematology Clinic. One of the Laboratory’s strengths lies in the very tight interaction between researchers, the Haematology cell therapy unit (UTCH) and the clinicians responsible for innovative clinical protocols. The Laboratory brings together a range of skills that make it possible to run projects taking different approaches: cellular and molecular biology, immunology, genomics and next generation sequencing (NGS) and cell therapy. 

The Experimental Haematology Laboratory is essentially active in three key areas:

  • the immune microenvironment in acute leukaemia
  • carcinogenesis induced by the oncoretroviruses HTLV-1 and BLV
  • immunosenescence in patients suffering from lymphoma and chronic lymphoid leukaemia.

Our research has some very important spin-off effects, not only in improving our understanding of the immune system but also in defeating leukaemia and developing clinical decision tools. The new therapeutic approaches based on the immune system promise to be less toxic and more effective in the long term.

Research projects

Project 1

Epigenetic regulation of the immune microenvironment in acute leukaemia - FOCUS ON T REGULATORY LYMPHOCYTES AND MICROARNS

Project 2

STUDY OF THE ANTICANCER, EPIGENETIC AND IMMUNOMODULATING EFFECT OF BIOACTIVE MOLECULES IN THE CASE OF LEUKEMIA AND LYMPHOMA  

Project 3

EXPLORING CLONAL ARCHITECTURE AS A BIOMARKER TO PREDICT HTLV-1 ASYMPTOMATIC CARRIERS AT HIGH RISK OF PROGRESSION TO AGGRESSIVE LEUKEMIA
  • Project leader : Anne Van den Broeke
  • Collaborations : 
    • Toshiki Watanabe, Laboratory of Tumor Cell Biology and Joint Study of Predisposing Factors for ATL Development (JSPFAD), University of Tokyo, Tokyo, Japan
    • Olivier Hermine, Hôpital Necker Enfants Malades and Institut Imagine, Paris, France
    • Michel Georges, GIGA Medical Genomics, Unit of Animal Genomics, Université de Liège, Belgium
    Funding : Les Amis de l'Institut Bordet, Télévie

Project 4

SINGLE-CELL GENOMICS TO IDENTIFY KEY DRIVERS THAT SHAPE TUMOR EVOLUTION AND ONCOGENIC SWITCH IN VIRUS-INDUCED CANCER 
  • Project leader : Anne Van den Broeke
  • Collaborations :
    • Michel Georges, GIGA Medical Genomics, Unit of Animal Genomics, Université de Liège, Belgium
    • Tristan Gilet, Mechanical Engineering Dpt, Microfluidics Lab, Université de Liège, Belgium
    • Philip Griebel, Vaccine and Infectious Disease Organization (VIDO-Intervac), University of Saskatchewan, Saskatoon, Canada
  • Funding : Les Amis de l'Institut Bordet, Télévie, International Brachet Stiftung (IBS), Fondation contre le Cancer

Projet 5

EXPLORING THE IMPACT OF INTEGRATED VIRAL GENOMES IN CARCINOGENESIS USING OXFORD NANOPORE LONG READ NGS TECHNOLOGIES: APPLICATION TO HUMAN PAPILLOMAVIRUS IN HNSCC CANCERS
  • Project leader : Anne Van den Broeke
  • Collaborations :
    • Head and Neck Surgery team IJB (A. Digonnet, E. Willemse, M. Quiriny, V. Donckier)
    • Anatomical Pathology and Tumor Biobank Dpts IJB (L. Craciun, P. Demetter)
    • Michel Georges, GIGA Medical Genomics, Unit of Animal Genomics, Université de Liège, Belgium
  • Funding : TelevieLes Amis de l'Institut BordetWALInnov

Our team

Laboratory Director
Philippe Lewalle

Researchers
Mehdi Najarsenior scientist

Makram  MerimiPhD, PhD, Scientifical collaborator 
Snehal KarpePost-doctoral fellow, Bioinformatician
Anne Van den BroekeDVM, PhD, Project Leader

Hugues Duvilliermanager of the Flow Cytometry Unit.

PhD students:
Redouane Rouas

- Khalid Ottmani
Douäa Moussa Agha
- Fatima Bouhtit

Administrative Assistance
- Catherine Primo

10/02/2022

 Scientific publications

OncomiRs as noncoding RNAs having functions in cancer: Their role in immune suppression and clinical implications.

Authors : Otmani K, Rouas R, Lewalle P
Year : 2022
Journal : Front Immunol
Volume : 13
Pages : 913951

Fundamental and Applied Advances in Stem Cell Therapeutic Research.

Authors : Merimi M, Rahmani S, Afailal Tribak A, Bouhtit F, Fahmi H, Najar M
Year : 2022
Journal : Cells
Volume : 11

Outcomes after allogeneic hematopoietic stem cell transplantation for adults with primary mediastinal B cell lymphoma: a SFGM-TC and LYSA study.

Authors : Le Calvez B, Tessoullin B, Renaud L, Botella-Garcia C, Srour M, Le Gouill S, Guillerm G, Gressin R, Nguyen Quoc S, Furst S, Chauchet A, Sibon D, Lewalle P, Poiré X, Maillard N, Villate A, Loschi M, Paillassa J, Beguin Y, Dulery R, Tudesq JJ, Fayard A, Béné MC, Camus V, Chevallier P, Le Bourgeois A
Year : 2022
Journal : Acta Oncol
Pages : 1-7

Therapeutic Mesenchymal Stem/Stromal Cells: Value, Challenges and Optimization.

Authors : Najar M, Melki R, Khalife F, Lagneaux L, Bouhtit F, Moussa Agha D, Fahmi H, Lewalle P, Fayyad-Kazan M, Merimi M
Year : 2022
Journal : Front Cell Dev Biol
Volume : 9
Pages : 716853

New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy.

Authors : Andreozzi F, Massaro F, Wittnebel S, Spilleboudt C, Lewalle P, Salaroli A
Year : 2022
Journal : Int J Mol Sci
Volume : 23